organization · Reporting owner
HBM Healthcare Investments (Cayman) Ltd.
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nabriva Therapeutics Legacy plcNBRV · Entity 174291 | 10% owner | July 19, 2017 | July 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nabriva Therapeutics Legacy plc
Report date July 19, 2017 · Filed July 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,397,922 |
Ending reported balance
After 2017-07-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-07-19 · Sale · Disposed 20,786 · Balance 2,421,367 Row 2 · 2017-07-20 · Sale · Disposed 23,445 · Balance 2,397,922 |
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IO Biotech, Inc.
Report date November 09, 2021 · Filed November 12, 2021
Section 16 reporting ended · disclosed 2021-11-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,690,545 |
Ending reported balance
After 2021-11-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-11-09 · Conversion · Acquired 2,365,545 · Balance 2,365,545 F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. Row 2 · 2021-11-09 · Purchase · Acquired 325,000 · Balance 2,690,545 |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-09 · Conversion · Disposed 188,168 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.
Mineralys Therapeutics, Inc.
Report date February 14, 2023 · Filed February 17, 2023
Section 16 reporting ended · disclosed 2023-02-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,218,106 |
Ending reported balance
After 2023-02-14 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2023-02-14 · Conversion · Acquired 1,941,368 · Balance 1,941,368 F1: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date. Row 2 · 2023-02-14 · Conversion · Acquired 964,238 · Balance 2,905,606 F2: Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date. Row 3 · 2023-02-14 · Purchase · Acquired 312,500 · Balance 3,218,106 |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-02-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-02-14 · Conversion · Disposed 20,962,895 · Balance 0 F1: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-02-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-02-14 · Conversion · Disposed 10,411,846 · Balance 0 F2: Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date.
F2: Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date.
Nabriva Therapeutics plc
Report date September 12, 2017 · Filed September 15, 2017
Section 16 reporting ended · disclosed 2017-09-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,360,278 |
Reported balance
After 2017-09-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-09-12 · Sale · Disposed 10,458 · Balance 2,360,278 F1: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.53 to $8.825. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price. F2: The balance was adjusted by one (1) share to account for a mathematical error in a prior filing. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,337,557 |
Reported balance
After 2017-09-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-09-13 · Sale · Disposed 22,721 · Balance 2,337,557 F3: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.5 to $8.685. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price |
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,334,128 |
Reported balance
After 2017-09-14 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2017-09-14 · Sale · Disposed 3,429 · Balance 2,334,128 F4: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.5 to $8.6386. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.53 to $8.825. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price.
F2: The balance was adjusted by one (1) share to account for a mathematical error in a prior filing.
F3: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.5 to $8.685. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price
F4: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.5 to $8.6386. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price.
Werewolf Therapeutics, Inc.
Report date May 04, 2021 · Filed May 05, 2021
Section 16 reporting ended · disclosed 2021-05-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 625,995 |
Reported balance
After 2021-05-04 transaction · row 1
1 source rowRow 1 · 2021-05-04 · Conversion · Acquired 625,995 · Balance 625,995 F1: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-05-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-04 · Conversion · Acquired 5,426,819 · Balance 0 F1: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2023 Filed Feb 17, 2023 02:00 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | ConversionSeries B Preferred Stock · Derivative | 10,411,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-022971 · tm235636-2_4seq1.xml · derivative · entry 5 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 964,238 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date. F2 · derivative.exercise_date: Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date. F2 · derivative.expiration_date: Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date. Read SEC document |
| February 14, 2023 Filed Feb 17, 2023 02:00 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | ConversionSeries A Preferred Stock · Derivative | 20,962,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-022971 · tm235636-2_4seq1.xml · derivative · entry 4 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,941,368 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date. Read SEC document |
| February 14, 2023 Filed Feb 17, 2023 02:00 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | PurchaseCommon Stock | 312,500 | $16.00 | $5,000,000.00 |
DisclosureSEC source: 0001104659-23-022971 · tm235636-2_4seq1.xml · nonDerivative · entry 3 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,218,106 Read SEC document |
| February 14, 2023 Filed Feb 17, 2023 02:00 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | ConversionCommon Stock | 964,238 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-022971 · tm235636-2_4seq1.xml · nonDerivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,905,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date. Read SEC document |
| February 14, 2023 Filed Feb 17, 2023 02:00 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | ConversionCommon Stock | 1,941,368 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-022971 · tm235636-2_4seq1.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,941,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:16 UTC | IO Biotech, Inc. IOBT · Entity 8764 | ConversionSeries C Preferred Stock · Derivative | 188,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-138088 · tm2131875-2_4seq1.xml · derivative · entry 3 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,365,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:16 UTC | IO Biotech, Inc. IOBT · Entity 8764 | PurchaseCommon Stock | 325,000 | $14.00 | $4,550,000.00 |
DisclosureSEC source: 0001104659-21-138088 · tm2131875-2_4seq1.xml · nonDerivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,690,545 Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:16 UTC | IO Biotech, Inc. IOBT · Entity 8764 | ConversionCommon Stock | 2,365,545 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-138088 · tm2131875-2_4seq1.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,365,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. Read SEC document |
| May 04, 2021 Filed May 5, 2021 20:00 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionSeries B Preferred Stock · Derivative | 5,426,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061692 · a4.xml · derivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 625,995 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| May 04, 2021 Filed May 5, 2021 20:00 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionCommon Stock | 625,995 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-061692 · a4.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 00:21 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleOrdinary Shares | 3,429 | $8.52 | $29,223.65 |
DisclosureSEC source: 0001179110-17-012310 · edgar.xml · nonDerivative · entry 3 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,334,128 F4 · price: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.5 to $8.6386. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 00:21 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleOrdinary Shares | 22,721 | $8.54 | $193,955.54 |
DisclosureSEC source: 0001179110-17-012310 · edgar.xml · nonDerivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,337,557 F3 · price: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.5 to $8.685. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price Read SEC document |
| September 12, 2017 Filed Sep 15, 2017 00:21 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleOrdinary Shares | 10,458 | $8.63 | $90,235.81 |
DisclosureSEC source: 0001179110-17-012310 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,360,278 F1 · price: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $8.53 to $8.825. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price. F2 · balance_after: The balance was adjusted by one (1) share to account for a mathematical error in a prior filing. Read SEC document |
| August 31, 2017 Filed Sep 6, 2017 00:18 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleOrdinary Shares | 639 | $9.50 | $6,070.50 |
DisclosureSEC source: 0001179110-17-012037 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,370,735 Read SEC document |
| August 08, 2017 Filed Aug 10, 2017 00:54 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleOrdinary Shares | 2,013 | $10.50 | $21,137.10 |
DisclosureSEC source: 0001179110-17-011313 · edgar.xml · nonDerivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,371,374 F1 · price: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $10.50 to $10.51. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price. Read SEC document |
| August 07, 2017 Filed Aug 10, 2017 00:54 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleOrdinary Shares | 17,790 | $10.50 | $186,795.00 |
DisclosureSEC source: 0001179110-17-011313 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,373,387 F1 · price: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $10.50 to $10.51. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price. Read SEC document |
| July 28, 2017 Filed Aug 2, 2017 01:21 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleOrdinary Shares | 6,585 | $10.51 | $69,195.18 |
DisclosureSEC source: 0001179110-17-010929 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,391,177 F1 · price: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $10.50 to $10.55. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price. Read SEC document |
| July 24, 2017 Filed Jul 27, 2017 01:03 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleOrdinary Shares | 160 | $10.50 | $1,680.00 |
DisclosureSEC source: 0001179110-17-010725 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,397,762 Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:36 UTC | Nabriva Therapeutics Legacy plc NBRV · Entity 174291 | SaleOrdinary Shares | 23,445 | $10.50 | $246,172.50 |
DisclosureSEC source: 0001179110-17-010624 · edgar.xml · nonDerivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,397,922 Read SEC document |
| July 20, 2017 Filed Jul 25, 2017 01:10 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleOrdinary Shares | 23,445 | $10.50 | $246,172.50 |
DisclosureSEC source: 0001179110-17-010640 · edgar.xml · nonDerivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,397,922 Read SEC document |
| July 19, 2017 Filed Jul 22, 2017 01:36 UTC | Nabriva Therapeutics Legacy plc NBRV · Entity 174291 | SaleOrdinary Shares | 20,786 | $10.50 | $218,253.00 |
DisclosureSEC source: 0001179110-17-010624 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,421,367 Read SEC document |
| July 19, 2017 Filed Jul 25, 2017 01:10 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleOrdinary Shares | 20,786 | $10.50 | $218,253.00 |
DisclosureSEC source: 0001179110-17-010640 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,421,367 Read SEC document |
| July 18, 2017 Filed Jul 19, 2017 01:03 UTC | Nabriva Therapeutics Legacy plc NBRV · Entity 174291 | SaleOrdinary Shares | 1,339 | $10.50 | $14,059.50 |
DisclosureSEC source: 0001179110-17-010441 · edgar.xml · nonDerivative · entry 3 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,442,153 Read SEC document |
| July 17, 2017 Filed Jul 19, 2017 01:03 UTC | Nabriva Therapeutics Legacy plc NBRV · Entity 174291 | SaleOrdinary Shares | 47,460 | $10.50 | $498,415.43 |
DisclosureSEC source: 0001179110-17-010441 · edgar.xml · nonDerivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,443,492 F2 · price: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $10.50 to $10.64. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| July 14, 2017 Filed Jul 19, 2017 01:03 UTC | Nabriva Therapeutics Legacy plc NBRV · Entity 174291 | SaleOrdinary Shares | 21,055 | $10.53 | $221,789.16 |
DisclosureSEC source: 0001179110-17-010441 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,490,952 F1 · price: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $10.50 to $10.64. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| July 13, 2017 Filed Jul 14, 2017 01:22 UTC | Nabriva Therapeutics Legacy plc NBRV · Entity 174291 | SaleOrdinary Shares | 39,914 | $10.54 | $420,757.42 |
DisclosureSEC source: 0001179110-17-010365 · edgar.xml · nonDerivative · entry 3 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,512,007 F3 · price: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| July 12, 2017 Filed Jul 14, 2017 01:22 UTC | Nabriva Therapeutics Legacy plc NBRV · Entity 174291 | SaleOrdinary Shares | 13,740 | $10.50 | $144,271.37 |
DisclosureSEC source: 0001179110-17-010365 · edgar.xml · nonDerivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,551,921 F2 · price: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $10.50 to $10.52 Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| July 11, 2017 Filed Jul 14, 2017 01:22 UTC | Nabriva Therapeutics Legacy plc NBRV · Entity 174291 | SaleOrdinary Shares | 3,521 | $10.52 | $37,027.19 |
DisclosureSEC source: 0001179110-17-010365 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,565,661 F1 · price: The price reported in Column 4 is a weighted average price. These ordinary shares were sold in multiple transactions ranging from $10.50 to $10.59 Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| July 07, 2017 Filed Jul 8, 2017 01:29 UTC | Nabriva Therapeutics Legacy plc NBRV · Entity 174291 | SaleOrdinary Shares | 133 | $10.50 | $1,396.50 |
DisclosureSEC source: 0001179110-17-010236 · edgar.xml · nonDerivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,569,182 F1 · security: On June 23, 2017, Nabriva Therapeutics plc ("Nabriva plc") became the successor of Nabriva Therapeutics AG ("Nabriva AG") pursuant to an exchange offer. Pursuant to the exchange offer, each outstanding common share of Nabriva AG was exchanged for ten ordinary shares of Nabriva plc and each outstanding American Depositary Share of Nabriva AG, which represented one-tenth of one common share of Nabriva AG, was exchanged for one ordinary share of Nabriva plc. On prior reports filed by the reporting person subsequent to the completion of the exchange offer, all references to American Depositary Shares of Nabriva AG should be understood to refer to ordinary shares of Nabriva plc.. Read SEC document |
| July 05, 2017 Filed Jul 8, 2017 01:29 UTC | Nabriva Therapeutics Legacy plc NBRV · Entity 174291 | SaleOrdinary Shares | 2,562 | $10.52 | $26,960.44 |
DisclosureSEC source: 0001179110-17-010236 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,569,315 F1 · security: On June 23, 2017, Nabriva Therapeutics plc ("Nabriva plc") became the successor of Nabriva Therapeutics AG ("Nabriva AG") pursuant to an exchange offer. Pursuant to the exchange offer, each outstanding common share of Nabriva AG was exchanged for ten ordinary shares of Nabriva plc and each outstanding American Depositary Share of Nabriva AG, which represented one-tenth of one common share of Nabriva AG, was exchanged for one ordinary share of Nabriva plc. On prior reports filed by the reporting person subsequent to the completion of the exchange offer, all references to American Depositary Shares of Nabriva AG should be understood to refer to ordinary shares of Nabriva plc.. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $10.50 to $10.74 Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 00:58 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 11,352 | $10.95 | $124,249.91 |
DisclosureSEC source: 0001179110-17-010135 · edgar.xml · nonDerivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,571,877 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F3 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $10.59 to $11.12. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| June 30, 2017 Filed Jul 6, 2017 00:58 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 1,775 | $10.94 | $19,420.45 |
DisclosureSEC source: 0001179110-17-010135 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,583,229 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $10.50 to $11.08 Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 01:33 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 1,603 | $10.72 | $17,188.97 |
DisclosureSEC source: 0001179110-17-009806 · edgar.xml · nonDerivative · entry 3 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,585,004 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F4 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $10.61 to $10.81. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 01:33 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 4,789 | $11.10 | $53,157.90 |
DisclosureSEC source: 0001179110-17-009806 · edgar.xml · nonDerivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,586,697 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F3 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| June 27, 2017 Filed Jun 30, 2017 01:33 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 2,166 | $10.83 | $23,457.13 |
DisclosureSEC source: 0001179110-17-009806 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591,396 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $10.50 to $11.16. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| June 01, 2017 Filed Jun 6, 2017 01:41 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 400 | $11.27 | $4,508.00 |
DisclosureSEC source: 0001179110-17-008647 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,593,562 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 23:13 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 15,130 | $11.03 | $166,812.79 |
DisclosureSEC source: 0001179110-17-006295 · edgar.xml · nonDerivative · entry 3 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,593,962 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $11.00 to $11.15. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 23:13 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 100 | $11.00 | $1,100.00 |
DisclosureSEC source: 0001179110-17-006295 · edgar.xml · nonDerivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,609,092 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 23:13 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 709 | $11.00 | $7,799.00 |
DisclosureSEC source: 0001179110-17-006295 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,609,192 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. Read SEC document |
| April 21, 2017 Filed Apr 25, 2017 23:19 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 2,622 | $11.04 | $28,937.44 |
DisclosureSEC source: 0001179110-17-006201 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,609,901 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 00:29 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 325 | $11.00 | $3,575.00 |
DisclosureSEC source: 0001179110-17-006134 · edgar.xml · nonDerivative · entry 3 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,612,523 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 00:29 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 11,785 | $11.07 | $130,434.02 |
DisclosureSEC source: 0001179110-17-006134 · edgar.xml · nonDerivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,612,848 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F3 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $11.05 to $11.20. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| April 18, 2017 Filed Apr 21, 2017 00:29 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 11,822 | $11.16 | $131,880.32 |
DisclosureSEC source: 0001179110-17-006134 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,624,633 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $11.13 to $11.20. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| April 13, 2017 Filed Apr 14, 2017 01:12 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 10,984 | $11.13 | $122,232.15 |
DisclosureSEC source: 0001179110-17-005990 · edgar.xml · nonDerivative · entry 3 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,636,455 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F4 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $11.10 to $11.20. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| April 12, 2017 Filed Apr 14, 2017 01:12 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 13,250 | $11.22 | $148,653.08 |
DisclosureSEC source: 0001179110-17-005990 · edgar.xml · nonDerivative · entry 2 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,647,439 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F3 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $11.20 to $11.50. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| April 11, 2017 Filed Apr 14, 2017 01:12 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 8,597 | $11.40 | $98,034.17 |
DisclosureSEC source: 0001179110-17-005990 · edgar.xml · nonDerivative · entry 1 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,660,689 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $11.00 to $11.50. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 01:38 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleCommon Shares | 37,876 | $10.73 | $406,451.14 |
DisclosureSEC source: 0001179110-17-005914 · edgar.xml · nonDerivative · entry 5 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,394 F1 · price: The prices reported in Column 4 are a weighted average prices. These shares were sold in multiple transactions.Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 10:04 UTC Amendment | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleAmerican Depository Shares representing Common Shares | 37,876 | $10.73 | $406,451.14 |
DisclosureSEC source: 0001104659-17-022745 · a4a.xml · nonDerivative · entry 5 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,669,286 F1 · security: Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F2 · price: The prices reported in Column 4 are weighted average prices. These ADSs were sold in multiple transactions. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| April 07, 2017 Filed Apr 11, 2017 01:38 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleCommon Shares | 18,001 | $10.96 | $197,290.96 |
DisclosureSEC source: 0001179110-17-005914 · edgar.xml · nonDerivative · entry 4 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,270 F1 · price: The prices reported in Column 4 are a weighted average prices. These shares were sold in multiple transactions.Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
| April 07, 2017 Filed Apr 11, 2017 01:38 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleCommon Shares | 3,500 | $11.04 | $38,640.00 |
DisclosureSEC source: 0001179110-17-005914 · edgar.xml · nonDerivative · entry 3 HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,271 F1 · price: The prices reported in Column 4 are a weighted average prices. These shares were sold in multiple transactions.Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.